NCT00522301View on ClinicalTrials.gov

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

sorafenib tosylate

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (1)

10021

Memorial Sloan - Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bayer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER